Mostrando ítems 1-16 de 16
-
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Castellano, Daniel; González-Larriba, José L.; Antón-Aparicio, Luis M.; Cassinello, Javier; Grande-Pulido, E.; Esteban, Emilio; Sepúlveda, Juan (Expert Opinion on Pharmacotherapy, 2011)
-
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Pérez-Gracia, J. L.; Prior, C.; Guillén-Grima, F.; Segura, V.; González, A.; Panizo, A.; Melero, I.; Grande-Pulido, E.; Gurpide, A.; Gurpide, A.; Gil-Bazo, I.; Calvo, A. (British Journal of Cancer, 2009)
-
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Alfaro, C.; Suárez, N.; González, A.; Solano, S.; Erro, L.; Dubrot, J.; Palazón, A.; Hervas-Stubbs, S.; Gurpide, A.; López-Picazo, J.M.; Grande-Pulido, E.; Melero, I.; Pérez-Gracia, J. L. (British Journal of Cancer, 2009)
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-a as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Castellano, D.; García del Muro, X.; Pérez-Gracia, J. L.; González-Larriba, J. L.; Abrio, M. V.; Ruiz, M. A.; Pardo, A.; Guzmán, C.; Díaz Cerezo, S.; Grande-Pulido, E. (Annals of Oncology, 2009)
-
The potential role of sunitinib in gastrointestinal cancers other than GIST. Grávalos, Cristina; Grande-Pulido, E.; Gasent, Joan Manel (Critical Reviews in Oncology/Hematology, 2010)